News

Just a summary of all the news articles that we could source from different places. A good way to make an investment decision is also to look at how actively the company is engaging with news sources to keep them in the news. In this day and age its critical to have a media presence.

Please consider a small donation if you think this website provides you with relevant information  

   
Date Title Source
2024-03-21 1:6:29 pm ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results GlobeNewsWire
2024-03-15 3:0:0 am Wall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024 InvestorPlace
2024-03-07 1:5:0 pm ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day GlobeNewswire
2024-03-06 6:1:0 am ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024 GlobeNewswire
2024-02-26 6:1:0 am ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study GlobeNewswire
2024-02-22 6:1:0 am ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024 GlobeNewswire
2024-02-22 2:33:56 am Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term Simply Wall St.
2024-02-20 6:1:0 am ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter GlobeNewswire
2024-02-05 6:1:0 am ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting GlobeNewswire
   

Please consider a small donation if you think this website provides you with relevant information